Mirati Therapeutics Inc.

This phase 3 trial tested whether a combination of sitravatinib (a targeted drug) and nivolumab (an immunotherapy) works better than docetaxel (standard chemo) for people with advanced non-squamous non-small cell lung cancer that got worse after platinum chemo and checkpoint inhi…

This study looked at the safety and effectiveness of continuing sitravatinib, a targeted cancer drug, either alone or combined with other therapies like nivolumab or pembrolizumab, in people with advanced or metastatic solid tumors. It enrolled 52 patients who were already benefi…